Back to top
more

Cellect Biotechnology Ltd. (APOP)

(Delayed Data from NSDQ)

$0.84 USD

0.84
181,722

-0.02 (-2.26%)

Updated May 3, 2019 03:56 PM ET

After-Market: $0.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Brokerage Reports

0 items in cart

Quoin Pharmaceuticals, Ltd. Sponsored ADR [APOP]

Reports for Purchase

Showing records 1 - 20 ( 24 total )

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 1

02/01/2019

Company Report

Pages: 4

Discontinuing coverage due to reallocation of resources

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 2

12/12/2018

Company Report

Pages: 4

Anticipating Further Catalysts in 2019; 3Q18 Financial Results Reported; Modulating Target to $12

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Medical - Biomedical and Genetics

Record: 3

10/23/2018

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for APOP

Provider: ValuEngine, Inc

Price: 25.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 4

08/29/2018

Company Report

Pages: 4

Patent Estate Broadened; 2Q18 Financial Results Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 5

07/16/2018

Company Report

Pages: 4

Swiss Biotech Center Agreement Inked; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 6

07/06/2018

Company Report

Pages: 4

Dresden University denovoMATRIX Collaboration Inked; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 7

05/29/2018

Company Report

Pages: 4

1Q 2018 Financial Results Reported; Looking Ahead to Further ApoGraft Data

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 8

02/26/2018

Company Report

Pages: 4

Financial Position Solid; Anticipating Additional ApoGraft Data in 2018

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 9

01/05/2018

Company Report

Pages: 4

Initial Clinical Safety Data Appears Promising; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 10

09/25/2017

Company Report

Pages: 4

Orphan Drug Status Granted; Solid Financial Position; Raising Price Target to $14

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 11

04/04/2017

Company Report

Pages: 4

Progress Made on Multiple Fronts; Reiterate Buy and Raising Price Target to $12

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 12

04/04/2017

Company Report

Pages: 4

Progress Made on Multiple Fronts; Reiterate Buy and Raising Price Target to $12

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 13

03/27/2017

Company Report

Pages: 4

4Q16 and FY2016 Financial Results Reported ; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 14

03/27/2017

Company Report

Pages: 4

4Q16 and FY2016 Financial Results Reported ; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 15

02/22/2017

Company Report

Pages: 4

Positive Clinical Data in Healthy Donors; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 16

02/22/2017

Company Report

Pages: 4

Positive Clinical Data in Healthy Donors; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 17

02/15/2017

Company Report

Pages: 4

Plan to Voluntarily Delist From Tel Aviv Stock Exchange; Reiterate Buy

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 18

02/15/2017

Company Report

Pages: 4

Plan to Voluntarily Delist From Tel Aviv Stock Exchange; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 19

02/09/2017

Company Report

Pages: 4

First Cancer Patient Treated in ApoGraft Trial.

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Quoin Pharmaceuticals, Ltd. Sponsored ADR

Industry: Unclassified

Record: 20

02/09/2017

Company Report

Pages: 4

First Cancer Patient Treated in ApoGraft Trial; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party
// eof